• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Invivyd Inc.

    11/14/25 11:55:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    INVIVYD, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    00534A102

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00534A102


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,383,077.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,383,077.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,383,077.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.1 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    CUSIP No.
    00534A102


    1Names of Reporting Persons

    Janus Henderson Biotech Innovation Master Fund Ltd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    21,576,145.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    21,576,145.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    21,576,145.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.3 %
    12Type of Reporting Person (See Instructions)

    IV


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    INVIVYD, INC.
    (b)Address of issuer's principal executive offices:

    1601 TRAPELO ROAD, SUITE 178 WALTHAM, MA 02451
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    00534A102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 25,383,077 shares
    (b)Percent of class:

    12.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    25383077

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    25383077

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:11/14/2025
     
    Janus Henderson Biotech Innovation Master Fund Ltd
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:11/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $IVVD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    11/25/2025Buy → Hold
    D. Boral Capital
    10/6/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Invivyd Inc.

    SCHEDULE 13G - Invivyd, Inc. (0001832038) (Subject)

    11/25/25 4:01:38 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Invivyd, Inc. (0001832038) (Filer)

    11/24/25 7:06:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Invivyd, Inc. (0001832038) (Filer)

    11/19/25 5:23:35 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Invivyd downgraded by D. Boral Capital

    D. Boral Capital downgraded Invivyd from Buy to Hold

    11/25/25 8:11:06 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Invivyd with a new price target

    Cantor Fitzgerald initiated coverage of Invivyd with a rating of Overweight and set a new price target of $10.00

    10/6/25 8:27:43 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd upgraded by Guggenheim with a new price target

    Guggenheim upgraded Invivyd from Neutral to Buy and set a new price target of $9.00

    4/5/24 7:50:41 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Bolno Paul

    4 - Invivyd, Inc. (0001832038) (Issuer)

    9/24/25 5:07:54 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bolno Paul

    3 - Invivyd, Inc. (0001832038) (Issuer)

    9/24/25 5:04:38 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

    NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 2:35 p.m. ET in Miami, FL. A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 90 days following the presentation. About InvivydInvivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform uni

    11/25/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

    VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd's proprietary antibody discovery technology platformVBY329 meets Invivyd's target profile of higher potency and improved barrier to resistance compared to standard of care RSV medicines, as assessed in vitro: Antiviral potency 1.5-fold greater on average than nirsevimab and 1.2-fold greater on average than clesrovimab against established authentic RSV strains representing circulating variantsResistance profile compared to nirsevimab reflects up to approximately 500-fold greater enhanced neutralization activity against RSV F protein variants resis

    11/24/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

    NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (NASDAQ:IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 6,000,000 shares of its common stock at a price of $2.4999 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Invivyd. The purchase price per share of each pre-funded warrant represents the per share offering price for the common s

    11/17/25 10:40:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Financials

    Live finance-specific insights

    View All

    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

    NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company's investor relations website shortly after the event. About Invivyd Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical c

    11/3/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

    PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization dosesVYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025 WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIR

    5/15/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

    WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two

    5/8/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

    NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek's 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm's healthcare p

    9/17/25 7:01:20 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 4:30:58 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 9:16:35 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care